ArticleFrontiers in immunology2026
Population waning trajectories of vaccine-induced tetanus immunity in Zhejiang, China.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Tetanus that occurs outside the neonatal period is not a statutory reporting disease in many regions, and few countries have comprehensive surveillance systems. To assess the level and durability of vaccine-induced tetanus immunity in a healthy population in Zhejiang, where long-term population-based data on non-neonatal tetanus immunity remain limited. Methods: A cross-sectional study was conducted in 2024 among 3,659 healthy individuals. Anti-tetanus toxoid IgG concentrations were measured by ELISA and expressed in IU/mL. Population immunity was evaluated by geometric mean concentration (GMC), seropositivity (≥0.01 IU/mL), and seroprotection (≥0.1 IU/mL). Antibody persistence was estimated according to age- and dose-specific antibody profiles. Generalized additive models (GAMs) with smoothing functions for the time since last doses were used to model nonlinear antibody trajectories overall, gender, and by dose group. Results: The overall Geometric Mean Concentration (GMC) of tetanus IgG antibodies was 0.064 IU/mL, with seropositivity (≥0.01 IU/mL) and seroprotection (≥0.1 IU/mL) rates of 85.05% and 52.94%, respectively. GMC peaked at 0.175 IU/mL in children aged 6-11 months, remained relatively high through 2 years of age, and then generally declined to 0.008 IU/mL in adults aged 40-59 years. By dose, GMC increased from 0.013 IU/mL in the 0-dose group to 0.156 IU/mL in the 3-dose group, then declined after 4 and 5 doses. Seroprotection exceeded 89% after 2-3 doses. GAM-fitted trajectories showed a rapid post-vaccination peak followed by gradual waning, with antibody levels remaining above 0.1 IU/mL for 8.81 years overall. Waning was slower in men than in women (7.87 vs. 6.66 years), and the estimated duration of seroprotection was 6.03, 12.86, and 3.07 years after three, four, and five doses, respectively. Conclusions: A high seropositivity rate does not necessarily indicate durable seroprotection against tetanus. Booster immunization strategies should incorporate both vaccination history and time since the last dose to sustain long-term protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.